BR112013005448A2 - peptídeos de ttll4 e vacinas contendo os mesmos. - Google Patents

peptídeos de ttll4 e vacinas contendo os mesmos.

Info

Publication number
BR112013005448A2
BR112013005448A2 BR112013005448A BR112013005448A BR112013005448A2 BR 112013005448 A2 BR112013005448 A2 BR 112013005448A2 BR 112013005448 A BR112013005448 A BR 112013005448A BR 112013005448 A BR112013005448 A BR 112013005448A BR 112013005448 A2 BR112013005448 A2 BR 112013005448A2
Authority
BR
Brazil
Prior art keywords
peptides
presenting cells
methods
present
peptide
Prior art date
Application number
BR112013005448A
Other languages
English (en)
Inventor
Osawa Ryuji
Tsunoda Takuya
Nakamura Yusuke
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BR112013005448A2 publication Critical patent/BR112013005448A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

peptídeos de ttll4 e vacinas contendo os mesmos. a presente invenção refere-se a vacinas peptídicas contra o câncer. em particular, peptídeos epitópicos derivados do gene de ttll4 que estimulam ctls são fornecidos. células que apresentam antígeno e ctls isolados que objetivam tais peptídeos, bem como métodos para indução das células que apresentam antígeno ou ctl são também fornecidos. a presente invenção proporciona ainda composição farmacêuticas contendo os peptídeos derivados de ttll4 ou polinucleotídeos que codificam os polipeptídeos como ingredientes ativos. além disso, a presente invenção fornece métodos para o tratamento e/ou profilaxia (isto é, prevenção) de cânceres (tumores) e/ou a prevenção de uma recorrência pós-operatória dos mesmos, bem como métodos para indução de ctls, métodos para indução de imunidade antitumor usando os peptídeos derivados de ttll4, polinucleotídeos que codificam os peptídeos ou células que apresentam antígeno que apresentam os peptídeos ou células que apresentam os peptídeos ou as composições farmacêuticas da presente invenção.
BR112013005448A 2010-09-07 2011-09-06 peptídeos de ttll4 e vacinas contendo os mesmos. BR112013005448A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38061110P 2010-09-07 2010-09-07
PCT/JP2011/004987 WO2012032764A1 (en) 2010-09-07 2011-09-06 Ttll4 peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
BR112013005448A2 true BR112013005448A2 (pt) 2019-09-24

Family

ID=45810374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005448A BR112013005448A2 (pt) 2010-09-07 2011-09-06 peptídeos de ttll4 e vacinas contendo os mesmos.

Country Status (13)

Country Link
US (1) US20130224234A1 (pt)
EP (1) EP2614146A4 (pt)
JP (1) JP2013540419A (pt)
KR (1) KR20130101529A (pt)
CN (1) CN103189510B (pt)
AU (1) AU2011300253B2 (pt)
BR (1) BR112013005448A2 (pt)
CA (1) CA2810636A1 (pt)
MX (1) MX2013002303A (pt)
RU (1) RU2013115434A (pt)
SG (1) SG187847A1 (pt)
TW (1) TW201210608A (pt)
WO (1) WO2012032764A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766927B2 (en) 2012-11-25 2020-09-08 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP4406607B2 (ja) * 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
WO2010023856A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Pancreatic cancer related gene ttll4

Also Published As

Publication number Publication date
CA2810636A1 (en) 2012-03-15
US20130224234A1 (en) 2013-08-29
SG187847A1 (en) 2013-03-28
RU2013115434A (ru) 2014-10-20
CN103189510A (zh) 2013-07-03
WO2012032764A1 (en) 2012-03-15
TW201210608A (en) 2012-03-16
EP2614146A4 (en) 2014-02-12
JP2013540419A (ja) 2013-11-07
MX2013002303A (es) 2013-10-28
AU2011300253B2 (en) 2015-01-15
CN103189510B (zh) 2015-05-06
KR20130101529A (ko) 2013-09-13
EP2614146A1 (en) 2013-07-17
AU2011300253A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
UA113729C2 (xx) Мутантний поліпептид інтерлейкіну-2 (il-2)
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
EA202091233A3 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
BR112012023621A2 (pt) composição dos peptídeos associados a tumor e vacina anticâncer relacionada para o tratamento do câncer gástrico e outros cânceres
BR112015021828A2 (pt) Peptídeos de kntc2 e vacinas que contêm os mesmos
MX2010014044A (es) Peptidos de epitope cdca1 y vacunas que contienen los mismos.
BR112015004349A2 (pt) peptídeos de ube2t e vacinas contendo os mesmos
UA114298C2 (uk) Пептид торк та вакцина, що його містить
MX2011012013A (es) Peptidos ttk y vacunas que incluyen los mismos.
BR112013005448A2 (pt) peptídeos de ttll4 e vacinas contendo os mesmos.
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
BR112015012234A2 (pt) Peptídios sema5b e vacinas contendo os mesmos
MX2011010191A (es) Peptidos c6orf167 y vacunas que continen los mismos.
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
EP4282883A3 (en) Cdca1-derived peptide and vaccine containing same
BR112017002193A2 (pt) peptídeo derivado de urlc10 e vacina contendo o mesmo
MX2012011666A (es) Peptidos cluap1 y vacunas que incluyen los mismos.
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.